Abstracts tagged "Cartilage Repair"

Abstract Number: 1485 • ACR Convergence 2020
LNA043, a Novel Cartilage Regenerative Treatment for Osteoarthritis: Results from a First-In-Human Trial in Patients with Knee Osteoarthritis
Celeste Scotti¹, Joseph Gimbel², Didier Laurent¹, Aviv Madar³, Thomas Peters¹, Yunyu Zhang³, Florine Polus¹, Michael Beste³, Igor Vostiar¹, Subhajit Choudhury⁴, Nicole Gerwin¹, Jörg Goldhahn⁵, Matthias Schieker¹ and Ronenn Roubenoff¹, ¹Novartis Institutes for BioMedical Research, Basel, Switzerland, ²Arizona Research Center, Phoenix, ³Novartis Institutes for BioMedical Research, Cambridge, ⁴Biostatistics & Pharmacometrics, Novartis Healthcare Pvt. Ltd., Hyderabad, India, ⁵Department of Health Sciences and Technology, ETH Zürich, Zurich, Switzerland
Background/Purpose:LNA043 is a modified human angiopoietin-like 3 (ANGPTL3) protein identified in a phenotypic screen for inducers of chondrogenesis and cartilage repair. The primary objective of…
Abstract Number: 1486 • ACR Convergence 2020
Long-term Efficacy and Safety of Intra-articular Sprifermin in Patients with Knee Osteoarthritis: Results from the 5-Year Forward Study
Felix Eckstein¹, Marc Hochberg², Hans Guehring³, Flavie Moreau⁴, Victor Ona⁴, Asger Bihlet⁵, Inger Byrjalsen⁵, Jeppe Andersen⁵, Benjamin Daelken³, Oliver Guenther³, Christoph Ladel³, Martin Michaelis³ and Philip G Conaghan⁶, ¹Paracelsus Medical University, Salzburg, Austria, ²University of Maryland School of Medicine, Baltimore, MD, ³Merck KGaA, Darmstadt, Germany, ⁴EMD Serono (a business of Merck KGaA, Darmstadt, Germany), Billerica, MA, ⁵Nordic Bioscience, Herlev, Denmark, ⁶Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and National Institute for Health Research Leeds Biomedical Research Centre, Leeds, United Kingdom
Background/Purpose: The 5-year Phase II FORWARD study assessed the efficacy and safety of the potential disease-modifying osteoarthritis drug (DMOAD) sprifermin (recombinant human fibroblast growth factor…